GlassScriptPhysician profile
Elana C Russell
NPI 1831589720
$16,626.93
in general payments reported to CMS, 2019-2025
52 companies · $3,146 in 2025
The $3,146 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,866 · 2022: $2,850 · 2023: $3,508 · 2024: $4,257 · 2025: $3,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $80.40 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,810.18 |
| Education | $80.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,382.60 | 2022-2025 | |
| Abbvie INC. | $1,310.78 | 2021-2025 | |
| Mdd US Operations, LLC | $1,170.62 | 2022-2025 | Gocovri, Xadago, Apokyn |
| Pfizer INC. | $993.39 | 2022-2025 | |
| Lundbeck LLC | $955.81 | 2021-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $833.72 | 2021-2025 | Mavenclad |
| Biogen, INC. | $833.58 | 2022-2025 | Vumerity, Spinraza, Skyclarys |
| Jazz Pharmaceuticals INC. | $826.35 | 2021-2025 | |
| Ucb, INC. | $799.17 | 2021-2025 | Rystiggo, Briviact, Zilbrysq |
| Amgen INC. | $766.78 | 2021-2025 | Uplizna, Aimovig |
| Amneal Pharmaceuticals LLC | $672.79 | 2021-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Neurocrine Biosciences, INC. | $628.73 | 2022-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $501.98 | 2021-2025 | |
| Lilly USA, LLC | $454.80 | 2021-2025 | Emgality, Reyvow, Kisunla |
| Biohaven Pharmaceutical Holding Company LTD. | $382.89 | 2022 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $376.54 | 2021-2024 | Nourianz |
| Biohaven Pharmaceuticals, INC. | $361.50 | 2021 | |
| Eisai INC. | $308.10 | 2021-2025 | |
| Csl Behring | $288.26 | 2021-2024 | Hizentra |
| Acadia Pharmaceuticals INC | $252.21 | 2021-2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $241.09 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $209.73 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $199.83 | 2022-2025 | Ultomiris |
| Impel Pharmaceuticals INC. | $167.67 | 2022-2023 | Trudhesa |
| Tg Therapeutics, INC. | $167.55 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $144.90 | 2021-2025 | Austedo, Austedo Xr |
| Harmony Biosciences LLC | $143.30 | 2021-2025 | Wakix |
| Argenx US, INC. | $132.24 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Axsome Therapeutics, INC. | $126.12 | 2023-2025 | Sunosi |
| Genzyme Corporation | $116.42 | 2021-2025 | |
| Neurelis, INC. | $88.95 | 2021-2024 | Valtoco |
| Nevro Corp. | $85.45 | 2022-2024 | Senza |
| Livanova USA, INC. | $83.77 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Astrazeneca Pharmaceuticals LP | $80.75 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $78.36 | 2021-2024 | Acthar |
| Tanabe Pharma America, INC. | $71.53 | 2022-2024 | |
| Merz Pharmaceuticals, LLC | $60.32 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Supernus Pharmaceuticals, INC. | $43.89 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $32.48 | 2023-2024 | Fycompa |
| Avion Pharmaceuticals | $30.67 | 2022 | |
| Banner Life Sciences, LLC | $28.29 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $25.77 | 2025 | Rexulti |
| Averitas Pharma INC. | $23.99 | 2024 | Qutenza |
| Avadel Cns Pharmaceuticals, LLC | $23.42 | 2024 | Lumryz |
| Avanir Pharmaceuticals, INC. | $16.57 | 2022 | |
| Abbott Laboratories | $16.47 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.12 | 2024 | Dojolvi |
| Genentech USA, INC. | $15.29 | 2023 | Ocrevus |
| Ge Healthcare | $14.27 | 2022 | |
| Globus Medical, INC. | $14.10 | 2025 | Omnia |
| Alnylam Pharmaceuticals INC. | $13.84 | 2021 | |
| Novo Nordisk INC | $13.18 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elana Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.